These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30499777)

  • 1. New Daily Persistent Headache and OnabotulinumtoxinA Therapy.
    Ali A; Kriegler J; Tepper S; Vij B
    Clin Neuropharmacol; 2019; 42(1):1-3. PubMed ID: 30499777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic subforms of new daily-persistent headache.
    Robbins MS; Grosberg BM; Napchan U; Crystal SC; Lipton RB
    Neurology; 2010 Apr; 74(17):1358-64. PubMed ID: 20421580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OnabotulinumtoxinA in pediatric chronic daily headache.
    Kabbouche M; O'Brien H; Hershey AD
    Curr Neurol Neurosci Rep; 2012 Apr; 12(2):114-7. PubMed ID: 22274570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine.
    Maasumi K; Thompson NR; Kriegler JS; Tepper SJ
    Headache; 2015 Oct; 55(9):1218-24. PubMed ID: 26381856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in the management of new daily persistent headache at a tertiary headache center-A retrospective real-world evidence study.
    Linnet T; Hussein M; Schytz HW; Bendtsen L; Amin FM
    Headache; 2024 May; 64(5):509-515. PubMed ID: 38646979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triggering Events and New Daily Persistent Headache: Age and Gender Differences and Insights on Pathogenesis-A Clinic-Based Study.
    Rozen TD
    Headache; 2016 Jan; 56(1):164-73. PubMed ID: 26474179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.
    Matharu M; Halker R; Pozo-Rosich P; DeGryse R; Manack Adams A; Aurora SK
    J Headache Pain; 2017 Dec; 18(1):78. PubMed ID: 28766236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
    Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU
    Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
    J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New daily persistent headache: a systematic review on an enigmatic disorder.
    Yamani N; Olesen J
    J Headache Pain; 2019 Jul; 20(1):80. PubMed ID: 31307396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Botulinum toxin A in chronic refractory migraine: premarketing experience].
    Álvaro-González LC; Fernández-García JM; Aranzábal-Alustiza I; Castillo-Calvo B; Iriondo-Etxenagusia I; Rodríguez-Antigüedad A
    Rev Neurol; 2012 Oct; 55(7):385-91. PubMed ID: 23011856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New daily persistent headache: should migrainous features be incorporated?
    Peng KP; Fuh JL; Yuan HK; Shia BC; Wang SJ
    Cephalalgia; 2011 Nov; 31(15):1561-9. PubMed ID: 21960650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache.
    Ahmed K; Oas KH; Mack KJ; Garza I
    Pediatr Neurol; 2010 Nov; 43(5):316-9. PubMed ID: 20933173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Mathew NT; Frishberg BM; Gawel M; Dimitrova R; Gibson J; Turkel C;
    Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
    Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An RCVS Spectrum Disorder? New Daily Persistent Headache Starting as a Single Thunderclap Headache (3 New Cases).
    Jamali SA; Rozen TD
    Headache; 2019 May; 59(5):789-794. PubMed ID: 30830966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.